Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 14.16% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 82.65% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 128.31% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 128.31% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 1794.98% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 447.95% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 1635.16% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 1178.54% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 493.61% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 721.92% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 539.27% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1132.88% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 173.97% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 265.3% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 858.9% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 173.97% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 721.92% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 356.62% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 1224.2% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 1041.55% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 1087.21% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/16/2022 | 14.16% | 查爾丹資本 | → $2.5 | 評級下調 | 購買→中性 |
| 09/09/2022 | 82.65% | 摩根士丹利 | $5 → $4 | 維護 | 等重 |
| 08/24/2022 | 128.31% | 摩根士丹利 | $6 → $5 | 維護 | 等重 |
| 08/15/2022 | 128.31% | 查爾丹資本 | $12 → $5 | 維護 | 買 |
| 11/02/2021 | 1794.98% | JMP證券 | $44 → $41.5 | 維護 | 市場表現強於大盤 |
| 11/01/2021 | 447.95% | 查爾丹資本 | → $12 | 升級 | 中性→購買 |
| 06/23/2021 | 1635.16% | JMP證券 | $36 → $38 | 維護 | 市場表現強於大盤 |
| 06/23/2021 | 1178.54% | 康託·菲茨傑拉德 | → $28 | 開始承保 | →超重 |
| 05/03/2021 | 493.61% | 摩根士丹利 | $14 → $13 | 維護 | 等重 |
| 04/12/2021 | 721.92% | 傑富瑞 | $11 → $18 | 升級 | 持有→購買 |
| 01/19/2021 | 539.27% | 摩根士丹利 | $6 → $14 | 維護 | 等重 |
| 12/23/2020 | 1132.88% | JMP證券 | → $27 | 開始承保 | →跑贏大盤 |
| 11/11/2020 | 173.97% | 摩根士丹利 | $8 → $6 | 維護 | 等重 |
| 05/21/2020 | 265.3% | 摩根士丹利 | → $8 | 評級下調 | 超重→等重 |
| 05/12/2020 | 858.9% | 蒙特利爾銀行資本 | $24 → $21 | 維護 | 跑贏大盤 |
| 05/12/2020 | 173.97% | 傑富瑞 | $18 → $6 | 評級下調 | 購買→Hold |
| 04/30/2019 | 721.92% | 傑富瑞 | → $18 | 開始承保 | →購買 |
| 01/29/2019 | 356.62% | 查爾丹資本 | → $10 | 開始承保 | →中性 |
| 10/12/2018 | 1269.86% | 摩根士丹利 | $29 → $30 | 維護 | 超重 |
| 10/11/2018 | 1269.86% | 摩根士丹利 | $29 → $30 | 維護 | 超重 |
| 06/04/2018 | 1224.2% | 摩根士丹利 | → $29 | 開始承保 | →超重 |
| 06/04/2018 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 06/04/2018 | 1041.55% | JMP證券 | → $25 | 開始承保 | →跑贏大盤 |
| 06/04/2018 | 1087.21% | 蒙特利爾銀行資本 | → $26 | 開始承保 | →跑贏大盤 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的目標價格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Chardan Capital on November 16, 2022. The analyst firm set a price target for $2.50 expecting EVLO to rise to within 12 months (a possible 14.16% upside). 4 analyst firms have reported ratings in the last year.
查爾丹資本於2022年11月16日報道了Evelo Biosciences(納斯達克：EVLO)的最新目標價。這家分析公司將目標價定為2.50美元，預計EVLO將在12個月內升至(可能上漲14.16%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的最新分析師評級是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Chardan Capital, and Evelo Biosciences downgraded their neutral rating.
Evelo Biosciences(納斯達克：EVLO)的最新分析師評級由查爾丹資本提供，Evelo Biosciences下調了中性評級。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences(EVLO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公開財務報表，與Evelo Biosciences的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Evelo Bioscience的上一次評級是在2022年11月16日提交的，所以你應該預計下一次評級將在2023年11月16日左右提供。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析師對Evelo Biosciences(EVLO)的評級正確嗎？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $2.50. The current price Evelo Biosciences (EVLO) is trading at is $2.19, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Evelo Biosciences(EVLO)評級被下調，目標價為0.00美元至2.50美元。Evelo Biosciences(EVLO)目前的交易價格為2.19美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。